[Correspondence] Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial – Authors' reply

We thank Justin Tondt and Vernon M Chinchilli for their comments on our analyses of the relationship between adiposity measures and major adverse cardiovascular event (MACE) benefit from semaglutide in the SELECT trial. To explore evidence for weight change as a prognostic marker, mechanism of actio